Compara mètodes

	Valoració Global Mèdica de l'Activitat Lúpica (PGA)	Índex d'Activitat de la Malaltia 28 (DAS28)	Índex d'Activitat de la Malaltia del Lupus Eritematós Sistèmic 2000 (SLEDAI-2K)
Camp	Reumatologia	Reumatologia	Reumatologia
Família	Process / pipeline	Process / pipeline	Process / pipeline
Any d'origen	1992	1995	2002
Autor original	Bombardier et al.	Prevoo et al.	Gladman et al.
Tipus	Clinician-rated	Clinician-rated	Clinician-rated
Font seminal	Petri M. Thermodynamic instability in the pathogenesis of lupus nephritis. Nat Rev Rheum. 2016;12(11):635-642.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
Àlies	Physician Global Assessment, PGA-Lupus, Clinician Global Assessment-SLE	DAS28, DAS28-CRP, DAS28-ESR	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
Relacionats	3	3	3
Resum	The Physician Global Assessment (PGA) is a clinician-rated, single-item measure of overall systemic lupus erythematosus (SLE) disease activity on a visual analogue scale (0–10). Used alongside structured indices like SLEDAI, PGA captures the clinician's integrated judgment of SLE severity, synthesising clinical examination, serology, imaging, and organ-specific findings into a holistic activity score. PGA is simple, practical, and widely used in SLE research and clinical practice as a complementary measure that reflects experienced clinician assessment of disease state.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.